Impact of Withdrawal of the Analgesic Co-proxamol on Nonfatal Self-Poisoning in the UK
Abstract
Background: In early 2005 the UK Committee on Safety of Medicines (CSM) announced gradual withdrawal of the analgesic co-proxamol because of its adverse benefit/safety ratio, especially its use for intentional and accidental fatal poisoning. Prescriptions of co-proxamol were reduced in the 3-year withdrawal phase (2005 to 2007) following the CSM announcement. Aims: To assess the impact of the CSM announcement in January 2005 to withdraw co-proxamol on nonfatal self-poisoning with co-proxamol and other analgesics. Methods: Interrupted time series analysis of general hospital presentations for nonfatal self-poisoning (five hospitals in three centers in England), comparing the 3-year withdrawal period 2005–2007 with 2000–2004. Results: A marked reduction in the number of episodes of nonfatal self-poisoning episodes involving co-proxamol was found following the CSM announcement (an estimated 62% over the period 2005 to 2007 compared to 2000 to 2004). There was no evidence of an increase in nonfatal self-poisoning episodes involving other analgesics (co-codamol, codeine, co-dydramol, dihydrocodeine, and tramadol) in relation to the CSM announcement over the same period, nor a change in the number of all episodes of self-poisoning. Limitations: Data were from three centers only. Conclusions: The impact of the policy appears to have reduced nonfatal self-poisoning with co-proxamol without significant substitution with other analgesics. This finding is in keeping with that for suicide.
References
2003). Licence needs to be changed. British Medical Journal, 327, 287.
(2006). Withdrawal of co-proxamol (distalgesic, cosalgesic, dolgesic). Current Problems in Pharmacovigilance, 31, 11.
. (1983). Distalgesic and its equivalents: Time for action. Drug and Therapeutics Bulletin, 21, 17–19.
. (2009). European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines. European Medicines Agency [online]. Retrieved from www.emea.europa.eu/pdfs/human/press/pr/40106209en.pdf
. (2007). Self-harm in England: A tale of three cities. Multicentre study of self-harm. Social Psychiatry and Psychiatric Epidemiology, 42, 513–521.
(2009). Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: Time series analysis. BMJ, 338, b2270.
(2003). Deliberate self-harm in Oxford, 1990–2000: a time of change in patient characteristics. Psychological Medicine, 33, 987–996.
(2003). Co-proxamol and suicide: A study of national mortality statistics and local nonfatal self-poisonings. BMJ, 326, 1006–1008.
(2005). A multicentre study of co-proxamol poisoning suicides based on coroners’ records in England. British Journal of Clinical Pharmacology, 59, 207–212.
(2005). Withdrawal of co-proxamol products and interim updated prescribing information CEM/CMO/2005/2. Medicines and Healthcare products Regulatory Agency (MHRA) [On-line]. Retrieved from www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con019461.pdf
. (2007). Deaths related to drug poisoning: England and Wales, 1993–2005. Health Statistics Quarterly, 33, 82–88.
. (2003). Interrupted time series designs in health technology assessment: Lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care, 19, 613–623.
(2008). Co-proxamol withdrawal has reduced suicide from drugs in Scotland. British Journal of Clinical Pharmacology, 66, 290–293.
(2005). Co-proxamol and suicide: A review to inform initiatives to prevent the continuing toll of overdose deaths. Quarterly Journal of Medicine, 98, 159–170.
(2007). Stata statistical software: Release 10. College Station, TX: Author.
. (2006). Prescription cost analysis: England 2005. Leeds: Department of Health.
. (2007). Prescription cost analysis: England 2006. Leeds: Department of Health.
. (2009a). FDA [On-line]. Retrieved from www.fda.gov/default.htm
. (2009b). FDA takes actions on Darvon, other pain medications containing propoxyphene. FDA [Online]. Retrieved from www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170769.htm
. (2002). Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics, 27, 299–309.
(2002). Estimating confidence intervals around relative changes in outcomes in segmented regression analyses of time series data. 15th Annual NESUG (NorthEast SAS Users Group Inc) Conference [On-line]. Retrieved from www.nesug.info/Proceedings/nesug02/st/st005.pdf.
(